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Abstract
Background: Overexpression of paternally expressed gene-10 (PEG10) is known to promote the progression of
several carcinomas, however, its role in pancreatic cancer (PC) is unknown. We investigated the expression and
function of PEG10 in PC.
Methods: PEG10 expression and correlation with PC progression was assessed in cancerous tissues and paired non-
cancerous tissues. Further, the role of PEG10 in PC cell progression and the underlying mechanisms were studied
by using small interfering RNA (Si-RNA).
Results: PEG10 expression was significantly higher in cancerous tissues and correlated with PC invasion of vessels
and Ki-67 expression. Si-RNA mediated PEG10 knockdown resulted in inhibition of proliferation and G0/G1 cell cycle
arrest, which was mediated by p21 and p27 upregulation. A decrease in PC cell invasion and migration, mediated
by ERK/MMP7 pathway, was observed in PEG10 knockdown group. Further, findings of ChIP assay suggested that
E2F-1 could directly enhance the expression of PEG10 through binding to PEG10 promoter.
Conclusions: In conclusion, PEG10 was identified as a prognostic biomarker for PC and E2F-1 induced PEG10 could
promote PC cell proliferation, invasion, and metastasis.
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Background
Pancreatic cancer (PC) is a highly invasive malignancy,
which is the fifth leading cause of cancer-related deaths
with a poor 5-year overall survival rate (<6%) [1]. Over
the past few decades, there has been a marked increase
in the incidence of PC [2]. Due to lack of obvious symp-
toms at the early stage of PC and a high rate of invasion
of blood vessels, lymph nodes, and nerves, treatment
through surgical resection is possible in less than 20% of
PC cases [3]. Furthermore, pancreatic fibrosis and other
factors lead to resistance to chemotherapy [4]. For these
reasons, identification of novel therapeutic and prog-
nostic biomarkers is a preferred approach for the
development of diagnosis and treatment of PC.
Several molecules have been recently reported to be
crucial for therapy and prognosis of PC, such as
MUC-4, LSD1, and FHL2 [5–7].
PEG10 (also known as EDR, HB-1, Mar2, MEF3L,
Mart2, and RGAG3) is a paternally expressed imprinted
gene which was first reported by Ono R et al. in 2001
[8]. PEG10 is expressed not only in brain, kidney, and
lung tissues in adults but also in embryonic tissues, such
as placenta [9]. Multiple functions have been attributed
to this gene, for example, it participates in cell prolifera-
tion and differentiation [10, 11], and inhibition of cell
apoptosis [12]. In addition, some studies have shown
that PEG10 was generally overexpressed in several kinds
of malignancies, such as lung cancer, hepatic cancer, and
B-cell chronic lymphocytic leukemia [13–15]. The over-
expression of PEG10 is significantly associated with the
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proliferation, progression, prognosis, and metastasis of
such malignancies.
However, the levels and role of PEG10 in patients with
PC have not been investigated extensively. Therefore, in
the present study we have assessed the expression of
PEG10 in pancreatic cancerous tissues and paired adja-
cent non-cancerous tissues by immunohistochemistry
(IHC). We have also evaluated whether there is a correl-
ation between PEG10 expression and clinicopathological
features of PC patients as well as their survival rate.




PEG10 mRNA expression for 178 pancreatic cancer pa-
tients were downloaded from The Cancer Genome Atlas
(TCGA) data portal (http://cancergenome.nih.gov/). A
total of 206 formalin-fixed, paraffin-embedded tissues,
including 103 cancerous tissues and 103 paired adjacent
non-cancerous tissues were obtained from patients diag-
nosed with PC at Pancreas Center, The First Affiliated
Hospital of Nanjing Medical University from 2005 to
2012. All patients received routine preoperative prepar-
ation and surgical therapy. The cancerous tissues and
paired adjacent non-cancerous tissues were respectively
integrated into relevant tissue microarray used for IHC
using microarray punching instrument. Our study was
approved by the Ethics Committee of the First Affiliated
Hospital of Nanjing Medical University. Written in-
formed consents were obtained from all patients under-
going surgery.
Reagents and antibodies
Anti-human PEG10 antibody was obtained from Novus
(Colorado, USA). Anti-human CDK4, CDK2, p21, p27,
SKP2, and E2F-1 antibodies were purchased from Cell
Signaling Technology (CST, Massachusetts, USA). Anti-
human Cyclin E1 antibody was obtained from Abcam.
Si-RNAs for PEG10 and E2F-1 and respective negative
controls were purchased from GenePharma. Annexin V
PE apoptosis detection kit was purchased from
eBioscience (Hatfield, UK) and PI/RNase staining buffer
was obtained from BD biosciences (New York, USA).
Cell counting kit-8 (CCK-8) and EDU kit were obtained
from Dojindo and RIBOBIO, respectively. Trizol reagent
and PrimeScript RT Master Mix (Perfect Real Time)
were both obtained from TaKaRa (Shiga, Japan) and
FastStart Universal SYBR Green Master was purchased
from Roche.
Cell lines and cell culture
Pancreatic cancer cell lines AsPC-1, Mia PaCa-2,
SW1990, BxPc-3, Capan-2, CFPAC-1, PANC-1 were
available in our laboratory. Normal human pancreatic
ductal cell line hTERT-HPNE was purchased from the
American Type Culture Collection (ATCC; Rockville,
MD, USA). Pancreatic cancer cell lines were cultured
in DMEM supplemented with 10% FBS, penicillin
(100 U/mL) and streptomycin (100 μg/mL). hTERT-
HPNE cell line was cultured according to the recom-
mendation of ATCC.
IHC analysis
Immunohistochemical staining was performed using a
standard immunoperoxidase staining procedure. The
tissue sections were viewed independently by two
experienced pathologists, who were blinded to the clini-
copathological information and clinical outcomes of the
patients enrolled in our study. The percentage of PEG10
positive cells was scored as follows: 0 (0%), 1 (1%), 2
(2%) …… 99 (99%), 100 (100%). The staining intensity
was visually scored as follows: 0 (negatively stained), 1
(weakly stained), 2 (moderately stained), and 3 (strongly
stained). Both the percentage of positive cancer cells and
staining intensity were decided independently by
double-blinded manner. IHC score for each case was
calculated by the following formula: IHC score = positive
rate score × intensity score. All patients were divided
into three groups (high, medium, and low) according
to the tri-sectional quantiles of PEG10 IHC score.
And then, cases with IHC score >50 (high and
medium) were regarded as high expression of PEG10;
on the contrary, cases with IHC score ≤50 (low) were
regarded as low expression.
Small interfering RNA and plasmid vector related assays
Cells were seeded in 12-well plates (1.8 × 105 cells/well)
and cultured in complete medium for 12 h. After re-
placing fresh complete medium, Si-RNAs (or plasmid
vector) and negative controls were added into relevant
wells using jetPRIME® transfection (Polyplus, NY, USA)
according to the manufacturer’s instructions. Following
transfection for 48–72 h, cells were collected for subse-
quent experiments.
Quantitative real time reverse transcription polymerase
chain reaction
Total RNA was extracted from different cell lines using
Trizol reagent and reverse-transcribed into cDNA with
PrimeScript RT Master Mix. The process of qRT-PCR
amplification was performed using the Step One Plus
Real-Time PCR System (Applied Biosystems, Carlsbad,
CA, USA) with FastStart Universal SYBR Green Master.
All the experiments mentioned here were performed ac-
cording to relevant manufacturer’s instructions. The spe-
cific primers for human PEG10, E2F-1, and β-ACTIN
were designed by Primer Premier 5 and checked by
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Oligo 6. The formula 2-ΔΔCt (Ct means the cycle thresh-
old) was used to normalize the relative expression of
PEG10 mRNA in certain cells.
Western blotting
Total protein was extracted by using a lysis buffer con-
taining PMSF, protease inhibitors, and phosphatase in-
hibitors (1 mL lysis buffer with 5 μl 100 mM PMSF,
1 μL protease inhibitors, and 5 μL phosphatase inhibi-
tors). Protein lysates from cells were subjected to 5×




Cells transfected with siRNA for PEG10 and negative
controls were plated in 96-well plates at a density of
2.5 × 103 cells/well. After culturing for 24 h, 100 μL
complete medium containing 10 μL CCK-8 reagent was
added to each well. Similarly, 100 μL completed medium
containing 10 μL CCK-8 reagent was added to respective
wells at different time points (24 h, 48 h, 72 h, 96 h, and
120 h). The plates were incubated in dark at 37 °C for
2 h and analyzed at 450 nm absorbance. At least three
wells were assessed for each group.
Clone formation assay
Different cell lines were seeded in 6-well plates (6 × 102
cells/well). The culture medium was changed every 2
days. The cells were stained with crystal violet after cul-
turing for 10 days. The number of clones was then
counted to evaluate cell proliferation.
EDU assay
Cells that had undergone different interventions were
seeded in 96-well plates at a density of 3 × 103 cells/well.
EDU assay was done as per manufacturer’s instructions
following 48 h culture. Cell proliferation was assessed by
calculating percentage of positive stained cells.
Apoptosis detection
Cells in each group were harvested after 48 h culture
and resuspended in 500 μL Annexin V binding buffer.
The cells were stained with 5 μL PE Annexin V and
7-AAD Viability Staining Solution and incubated in dark
at room temperature for 15 min before being analyzed
by flowcytometer (Gallios, Beckman Coulter, USA).
Cell cycle detection
Cells transfected with Si-RNA for PEG10 and negative
controls were cultured in serum-free medium for 24 h
and complete medium for 48 h. Harvested cells were
fixed in 70% formaldehyde at 4 °C for 5 h and stained
with 500 μL PI/RNase staining buffer. Stained cells were
then analyzed by flowcytometer.
Xenograft tumorigenicity assays
All female BALB/c nude mice aged 5 weeks used in this
study were purchased from Model Animal Research
Center of Nanjing University. To assess the function of
PEG10 in vivo, fresh cancer cells (1 × 106 per mice) were
implanted into the subcutaneous tissues which were in-
duced by 1% pentobarbital sodium. The mice were ran-
domly divided into two groups after four weeks of
tumor implantation. For each group, intratumoral injec-
tion with Si-RNA or negative control was performed
once every 48 h. Si-RNA and reagent (in vivo-jetPEI,
Polyplus, NY, USA) were separately added in 5% glucose
solution, and mixed them together. After a 15 min incu-
bation time at room temperature, the Si-RNA/ in vivo-
jetPEI® complexes were injected into animal. After
4 weeks, the mice executed humanely and the tumors
were excised and photographed.
Migration and invasion assays
Cell migration and invasion was assessed using transwell
filters purchased from BD Biosciences (Franklin Lakes,
NJ). PANC-1 (3 × 104) and CFPAC-1 (3 × 104) cells cul-
tured in serum-free medium for 24 h were seeded into
the upper chamber containing an uncoated or Matrigel-
coated membrane and 200 μL serum-free medium.
Complete medium (500 μL) was added to the lower
chamber. Cells that migrated to the lower compartment
were stained with crystal violet after 24 h of incubation
at 37 °C in a humidified 5% CO2 incubator. Three fields
in each well were randomly chosen to count migrated
and invaded cells.
Chromatin immunoprecipitation (ChIP)
ChIP assay was carried out using an EZ-Magna ChIP kit
(Millipore, Darmstadt, Germany) according to the man-
ufacturer’s protocol. Briefly, 2 × 106 cells were treated
with 1% formaldehyde for 10 min for crosslinking, and
then quenched by adding 0.125 M glycine. The cells
were scraped with PBS and collected after 5-min centri-
fugation at 800 × g at 4 °C. Then, the cross-linked cells
were resuspended in 1% SDS lysis buffer, and the soluble
chromatin was sheared into 400-bp fragment DNA using
an Ultrasonic Cell Disruptor (Covaris, USA). The frag-
mented chromatin samples were aliquoted as genomic
input DNA or immunoprecipitated with 5 ug E2F-1
antibodies, or rabbit IgG, and incubated at 4 °C with ro-
tation for 16 h. Immunocomplexes collected by mag-
netic separator were washed and eluted with 1% SDS
and 0.1 M NaHCO3, and DNA was purified on spin col-
umns. The ChIP products and genomic input DNA were
quantitatively analyzed by real-time PCR (E2F-1 primer
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sequences: forward, 5′- CCTGGAATTATTCTATCTT
GCAGAA-3′; reverse, 5′- AATGAATGAAATGCAGC
TTTTTAAC-3′). ChIP data are presented as the per-
centage of input normalized to control purifications.
Statistical analysis
The paired Student’s t-test was applied to compare
PEG10 expression in pancreatic cancerous and paired
non-cancerous tissues. The association of PEG10 ex-
pression with clinicopathologic features was analyzed
by the Pearson χ2 test. Survival analysis was assessed
by Kaplan Meier plots and log-rank tests. Independ-
ent prognostic factors were recognized through uni-
variate and multivariate Cox proportional hazard
regression models. The comparison between two
groups was done by independent Student’s t-test.
Stata 10.0 software was applied to process survival re-
lated analysis, and SPSS 20.0 software were used to
perform others. All data were expressed as mean ±
SD. Differences were considered statistically signifi-
cant at P < 0.05.
Results
The expression and roles of PEG10 in PC
PEG10 mRNA was generally expressed in PC tissues
(n = 178) according to the data obtained from TCGA.
PEG10 protein detected by IHC was significantly
overexpressed in 85 cancerous tissues compared to
paired non-cancerous tissues (Fig. 1a-c). Eighteen
pairs of tissues were excluded from the analyses be-
cause of the absence of target cells in cancerous and/
or non-cancerous cases . The association between
PEG10 expression and clinicopathological characteris-
tics is depicted in Table 1. High levels of PEG10 in
PC were markedly associated with some indicators of
PC progression, such as vessel invasion. Further, sur-
vival analysis suggested that PC patients with lower
expression of PEG10 could have a longer survival
time (Fig. 1d). Multivariate analysis suggested that
PEG10 was an independent prognostic factor for PC
(Table 2). PEG10 expression was positively associated
with Ki-67 expression, which is a biomarker of prolif-
eration (Fig. 1e). These data revealed that PEG10 was
abnormally upregulated in PC.
Fig. 1 The expression and roles of PEG10 in PC. a PEG10 mRNA expression in 178 PC samples obtained from TCGA was shown. b, c Higher expression
of PEG10 was observed in PC tissues than that in non-cancerous tissues by immunohistochemistry. d Overexpression of PEG10 was associated with
poorer prognosis of PC. e The immunohistochemistry scores of Ki-67 were positively correlated with that of PEG10
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Inhibition of PEG10 following Si-RNA transfection in
CFPAC-1 and PANC-1 cells
The expression of PEG10 was detected in AsPC-1, Mia
PaCa-2, SW1990, BxPc-3, Capan-2, CFPAC-1, PANC-1,
and hTERT-HPNE cells by qRT-PCR and western blot-
ting. Compared to hTERT-HPNE cells, higher expression
of PEG10 mRNA and protein were observed in PC cells,
especially CFPAC-1 and PANC-1 (Fig. 2a and b). There-
fore, CFPAC-1 and PANC-1 cells were selected to con-
duct Si-RNA related assays.
The interference efficiency of three Si-RNAs for PEG10
was confirmed through comparison with negative controls
at both mRNA and protein levels (Fig. 2c and d).
Si-RNA#2 could significantly decrease the production of
PEG10 and was chosen for further functional and mech-
anistic analyzes.
Si-RNA induced PEG10 downregulation suppresses PC cell
proliferation by arresting cell cycle in G0/G1 phase
Since PEG10 expression was positively associated with
Ki-67 expression, we further investigated whether PEG10
could affect PC cell proliferation.
Simultaneously, CCK-8, clone formation, and EDU as-
says were used to investigate the influence of PEG10 on
PC cell proliferation. The results of CCK-8 assay demon-
strated that the proliferation of Si-RNA transfected can-
cer cells was markedly reduced compared to negative
control transfected cells (Fig. 3a). The number of cell
clones in PEG10 downregulated cells was more than that
in control cells (Fig. 3b). EDU results also show similar
result with the percentage of positive stained cells being
significantly decreased in interference groups (Fig. 3c).
The interference efficiency of Si-RNA for PEG10 in vivo
was further confirmed by using IHC (Fig. 3d and e). Fur-
thermore, the volume and weight of the tumors obtained
from animal models injected with Si-RNA were both
lower than that treated with negative controls (Fig. 3f
and g). This data suggests that PEG10 could promote
PC cell proliferation in vitro and vivo.
Although we found that PEG10 could promote PC
cell proliferation, the mechanisms involved in this
phenomenon were still unclear. It is generally consid-
ered that cell apoptosis enhancement and/or cell cycle
arrest may inhibit the proliferation [16, 17]; however,
whether these processes contributed to mediation of
PC cell proliferation by lowering the expression of
PEG10 is not known.
As shown in Fig. 4a, the percentage of apoptotic cells
had no significant statistical differences between groups
showing PEG10 downregulation and negative control
groups. However, the percentage of G0/G1 phase cells in
PEG10 interfered cells was significantly higher than that
Table 1 Association of PEG10 expression with the
clinicopathological characteristics of PC











Lymph node metastasis ns
Absence 33 16
Presence 25 11






CA19-9a carbohydrate antigen 19–9, TNMb tumor-node-metastasis
*P < 0.05
Table 2 Univariate and multivariate analysis of the association of prognosis with clinicopathologic parameters and PEG10 expression in PC
Variable Univariable analysis Multivariable analysis
HRa (95% CIb) P HR (95% CI) P
CA19-9 (≤100 vs. > 100) 1.49 (0.92–2.42) 0.107 1.15 (0.70–1.90) 0.587
Histological grade (I/I–II/II vs. II–III/III) 1.90 (1.16–3.11) 0.011* 1.96 (1.17–3.30) 0.011*
TNM (I–IIA vs. IIB–IV) 1.28 (0.81–2.03) 0.298
Lymph node metastasis (Absence vs. Presence) 1.17 (0.72–1.91) 0.515
Blood vessel invasion (Absence vs. Presence) 1.96 (1.20–3.19) 0.007* 1.90 (1.14–3.15) 0.014*
Nerve invasion (Absence vs. Presence) 1.47 (0.86–2.54) 0.162 1.25 (0.71–2.21) 0.442
PEG10 expression (Low vs. High) 1.93 (1.12–3.34) 0.018* 1.85 (1.06–3.21) 0.030*
aHR hazard ratio, bCI confidence interval
*p < 0.05
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in control cells (Fig. 4b). This result indicated that
downregulation of PEG10 could induce G0/G1 phase ar-
rest to further suppress cell proliferation in PC.
To investigate how downregulation of PEG10 in-
duces G0/G1 phase arrest, the levels of several pro-
teins which play crucial roles in G0/G1 phase were
detected by western blotting. Cyclin E1 is reported to
accumulate from G0/G1 to S phase and reduce stead-
ily from S to G2/M phase. The abundant accumula-
tion of this molecule in G1/G0 generally indicates
G0/G1 arrest. Our results suggested that the levels of
Cyclin E1 were significantly higher in PEG10 knock-
down PC cells than that in control cells (Fig. 4c).
Furthermore, two regulators of cell cycle progression
at G1 phase, p21 and p27, were markedly upregulated
following PEG10 knockdown. The production of
CDK2 which is negatively regulated by p21 and p27
was significantly downregulated after PEG10 silencing
(Fig. 4c). Moreover, the expression of SKP2 was
downregulated following PEG10 silence (Fig. 4c).
These data suggested that interference of PEG10 in
PC cells could induce G0/G1 arrest by upregulation
of p21 and p27.
PEG10 promotes the migration and invasion of PC cells
through ERK/MMP7 pathway
Since higher PEG10 expression was significantly asso-
ciated with vessel invasion in PC samples, we specu-
lated that PEG10 may promote the migration and
invasion of PC cells.
As shown in Fig. 5a, the migration and invasion of PC
cells was significantly decreased following the downregu-
lation of PEG10. We further investigated the expression
of epithelial-mesenchymal transition (EMT) markers
and matrix metalloproteinases (MMPs) that are widely
reported to mediate the migration and invasion of can-
cer cells. Our results demonstrated that expression of
EMT markers was similar in different groups, but
MMP7 expression was markedly reduced in PEG10
knockdown cells (Fig. 5b and c). Although the mRNA of
MMP2 was both decreased in two pancreatic cancer cell
lines after the silence of PEG10. However, the protein of
Fig. 2 The interference efficiency of three Si-RNAs for PEG10. a, b The mRNA and protein expression of PEG10 in different PC cell lines were shown.
c, d The interference efficiency of three Si-RNAs for PEG10 was confirmed through both RT-PCR and western blotting
Peng et al. Journal of Experimental & Clinical Cancer Research  (2017) 36:30 Page 6 of 12
MMP2 was only decreased in CFPAC-1. Further, we ob-
served that reduction in phosphorylation of ERK may be
responsible for the downregulation of MMP7 (Fig. 5d).
These findings suggest that ERK/MMP7 pathway may
mediate the PEG10 induced migration and invasion of
PC cells.
E2F-1 directly regulates PEG10 expression
PEG10 is reported to be directly regulated by E2F-1 in
hepatocellular carcinoma and neuroendocrine prostate
cancer [18, 19]. However, whether E2F-1 regulates the
expression of PEG10 in PC cells was not known. To
evaluate we conducted ChIP assay and the results dem-
onstrate that E2F-1 could bind to the promoter of
PEG10 and the binding efficiency was respectively de-
creased or increased in E2F-1 knockdown or overexpres-
sion (Fig. 6a and b). The expression of PEG10 was also
decreased or increased in E2F-1 knockdown or overex-
pression cells at protein levels (Fig. 6c). Furthermore,
the proliferation, migration, and invasion of PC cells
were respectively inhibited or promoted after E2F-1
knockdown or overexpression (Fig. 6d and e). Data here
Fig. 3 The negative effects of PEG10 knockdown on PC cell proliferation. a-c The proliferation of PC cells was decreased following PEG10 downregulation
by Si-RNA in vitro. d, e The expression of PEG10 was decreased after PEG10 knockdown in vivo. f, g The weight and volume of tumors obtained from
animal models were decreased following PEG10 downregulation by Si-RNA in vivo. * represents P< 0.05,** represents P< 0.01, and *** represents P< 0.001
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suggested that E2F-1 could directly regulate PEG10 ex-
pression to further affect the cell proliferation, migra-
tion, and invasion in PC cells.
Discussion
In this study, we show that PEG10 was abnormally
overexpressed in PC and was significantly associated
with PC progression and prognosis. Furthermore,
E2F-1 mediated PEG10 upregulation could promote
PC cell proliferation, migration, and invasion. Thus,
we identified PEG10 as a potential prognostic and
therapeutic target for PC.
PEG10 is a paternally expressed imprinted gene, which
was reported to have been derived from the Ty3/Gypsy
family of retrotransposons [20]. Similar to many other
imprinted genes, the function of PEG10 is decided by its
expression levels or methylation level [21–23]. In our
study, we focused on the altered expression of PEG10 in
PC. During physiological conditions, adequate PEG10
expression is necessary for placental development and it
has been shown that PEG10 is downregulated in case of
preeclampsia [24–26]. PEG10 expression was later
shown to be abnormally reactivated in some malignan-
cies (such as liver cancer, lung cancer, and gallbladder
cancer) and that it could be a biomarker for progression
and prognosis of certain cancers [13, 27, 28]. The find-
ings of our study show for the first time that PEG10 is
highly expressed in PC and is associated with tumor size,
vessel invasion, and shorter overall survival time. Cox
proportional hazard regression analysis further illus-
trates that PEG10 is an independent factor for poor
prognosis of PC.
Furthermore, we also propose the role of PEG10 in PC
cell proliferation and the underlying mechanism. PEG10
has been reported to promote cancer cell proliferation
through mechanisms described as follows. PEG10 over-
expression was reported to be associated with a medi-
ator of apoptosis (SIAH1) resulting in decrease in cell
death as in hepatocellular carcinomas [12]. In neuroen-
docrine prostate cancer, PEG10 knockdown was shown
to suppress cell cycle progression through upregulation
of p21 and p27 and downregulation of CDK2 [19]. In
the present study, we also investigated the proliferation
promoting effect of PEG10 considering these two mech-
anisms; and the results were similar to the previously
published studies. Cell apoptosis rate in PEG10 knock-
down PC cells was similar to that in control cells. This
phenomenon may due to the inefficiency of PEG10 me-
diated anti-apoptosis effect or the presence of other
apoptosis regulatory mechanisms. However, the G0/G1
phase arrest in PEG10 knockdown PC cells was obvi-
ously observed. Further molecular mechanism analysis
suggested that expression of p21 and p27, which are
known cyclin-dependent kinase inhibitors, were signifi-
cantly increased in cells with PEG10 downregulation.
These molecules could inhibit the activation of CDK2
Fig. 4 The influence of PEG10 knockdown in PC cells on G0/G1 arrest. a The percentage of PC cell apoptosis was similar in each group.
b, c Downregulation of PEG10 in PC cells induced G0/G1 arrest through increasing the production of p21 and p27. * represents P < 0.05,**
represents P < 0.01, and *** represents P < 0.001
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and CDK4 through binding to them, as reported previ-
ously [29, 30]. However, the expression of CDK4 was
not significantly affected in cells with PEG10 downregu-
lation and control cells. Furthermore, the expression of
SKP2 was negatively associated with p27 which was
similar to the results of previous studies in pancreatic
cancer [31, 32]. Data related to cell cycle were consistent
with the studies described above.
Though the roles of PEG10 in PC cell prolifera-
tion, apoptosis, and cell cycle have been investigated
in the present study, the roles of this protein in
other aspects are relatively unknown. In previous
studies, it has been reported that PEG10 could in-
duce migration of Burkitt’s lymphoma cells via up-
regulation of MMP-2 and MMP-9 [33]. PEG10 has
been reported to promote lung cancer cell migration
and invasion by upregulating the expression of
β-catenin, MMP-2 and MMP-9, and decreasing the
expression of E-cadherin [13]. Further, PEG10 was
shown to trigger prostate cancer cell invasion by en-
hancing Snail expression via TGF-β signaling [19].
Our findings show that PEG10 expression is posi-
tively associated with vessel invasion in PC, and
PEG10 promotes PC cells migration and invasion
through ERK/MMP7 pathway. The MMP2 mRNA
was both decreased in two pancreatic cancer cell
lines after PEG10 knockdown. However, the protein
of MMP2 was only decreased in one of the cell lines
(CFPAC-1). Therefore, these data was not sufficient
to suggest that MMP2 was regulated by PEG10.
Fig. 5 The negative effects of PEG10 knockdown on migration and invasion of PC cells. a The migration and invasion of PC cells was decreased
in PEG10 downregulated groups. b The expression of EMT markers remained unchanged between two groups. c, d PEG10 triggered the migration
and invasion of PC cells through ERK/MMP7 pathway. * represents P < 0.05,** represents P < 0.01, and *** represents P < 0.001
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Although downstream events of PEG10 in PC have
been discussed preliminarily, the upstream events of this
protein are still unclear. E2F-1 is a member of the E2F
family of transcription factors, which plays a crucial role
in the control of cell cycle. E2F-1 has been reported to
regulate PEG10 expression via directly binding to the
promoter of PEG10 in liver and prostate cancer [18, 19].
Similar to these studies, our ChIP and western blotting
assay results also demonstrated that E2F-1 could interact
with PEG10 promoter to further upregulate PEG10 ex-
pression. Furthermore, PEG10 could also be regulated
by some other factors, such as c-MYC, CXCL13, CCL19,
Fig. 6 Direct regulation of transcription factor E2F-1 on PEG10 expression. a The interference efficiency of three Si-RNAs and plasmid vector for
E2F-1 was confirmed through both RT-PCR and western blotting. b, c E2F-1 could bind to the promoter of PEG10, and the binding efficiency and
PEG10 protein expression was decreased or increased in E2F-1 knockdown or overexpression groups. d, e The proliferation, migration, and invasion of
PC cells was affected after E2F-1 knockdown or overexpression. * represents P < 0.05,** represents P < 0.01, and *** represents P < 0.001
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and androgen receptor. Li et al. revealed that c-MYC,
which serves as a classic proto-oncogene, could act dir-
ectly upstream of proliferation-positive gene PEG10 [10].
Levels of PEG10 expression in freshly isolated B-ALL
and B-CLL CD19+CD34+ B cells has been shown to be
significantly increased after stimulation with CXCL13
and CCL19 together [34]. The upregulation of PEG10 in
this pattern may be involved in the resistance to TNF-α-
mediated apoptosis of B cells. Moreover, the interaction
between androgen and androgen receptor was firstly de-
scribed as a facilitating factor for PEG10 expression in
hepatic cancer [35], and then confirmed in gastric cancer
[36]. Whether the factors discussed above participate in
the activation of PEG10 in PC needs to be further
investigated.
Conclusions
We have demonstrated that an increased expression of
PEG10 is associated vessel invasion, and the overall sur-
vival time of PC patients. E2F-1 mediated PEG10
overexpression promotes PC cell proliferation via accel-
erating G0/G1 progression and increase migration and
invasion through ERK/MMP7 pathway. These results
suggest that PEG10 may serve as an oncogene in PC
pathogenesis and is a potential prognostic and thera-
peutic target for PC.
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